FCF establishes partnership with Dracen Pharmaceuticals

FCF is pleased to announce that it has entered into a partnership agreement with Dracen Pharmaceuticals, Inc. to supply a glutamine antagonist pro-drug, DRP-104 (sirpiglenastat), for a planned clinical trial in fibrolamellar patients. Under the agreement, Dracen will provide the product, as well as regulatory and operational support for the trial. In fibrolamellar carcinoma, recent …

Read more

Clinical Trials

Overview New medical tests and treatments aren’t offered to the public as soon as they’re discovered. They need to be appropriately studied to determine their safety and effectiveness. Clinical trials are formal research studies to evaluate a medical treatment. Clinical trials can study many things, including: According to the National Institutes of Health (NIH), a …

Read more

New clinical trial testing nivolumab, 5-FU, and interferon alpha-2b now open

A new clinical trial for fibrolamellar carcinoma (FLC) is now recruiting subjects at the University of Texas M.D. Anderson Cancer Center in Houston, Texas. This phase I/II trial studies the safety, tolerability, and effectiveness of a combination of nivolumab, 5-fluorouracil (5-FU), and interferon alpha-2b (IFN-α2b) for the treatment of fibrolamellar cancer that cannot be removed …

Read more

Sidney Kimmel Comprehensive Cancer Center photo

Opening of FLC peptide vaccine clinical trial

A new clinical trial of an immune therapy for fibrolamellar carcinoma (FLC) is now recruiting subjects at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, MD. The study asks if individuals can mount an effective immune response against FLC by specifically targeting the unique chimeric protein …

Read more